• Mehrdad Estakhr, Reza Tabrizi, Zahra Ghotbi, Saeed Shahabi, Adrina Habibzadeh, Ali Bashi, and Afshin Borhani-Haghighi.
• Clinical Neurology Research Center, Research Tower, Shiraz University of Medical Sciences, Khalili Ave., Shiraz, Iran.
• Am. J. Med. Sci. 2022 Sep 1; 364 (3): 264273264-273.

AbstractThe primary target of SARS-CoV-2 is the respiratory tract; nevertheless, the virus can invade extrapulmonary organs, such as the nervous system. Peripheral facial nerve palsy has been reported in COVID-19 cases as isolated, unilateral, or bilateral in the context of Guillain-Barré syndrome (GBS). In the present study, online databases, including PubMed and Google Scholar, were searched. Studies without focusing on isolated peripheral facial nerve palsy and SARS-CoV-2 were excluded. Finally, 36 patients with facial nerve palsy were included in our study using reverse transcriptase-polymerase chain reaction (RT-PCR) or antibody SARS-CoV-2 positive test. Interestingly, 23 (63.8%) of these patients had no typical history of COVID-19, and facial nerve palsy was their first clinical manifestation. The present study concludes that there is enough evidence to suggest that SARS-CoV-2 infection may present with facial nerve palsy as the initial clinical manifestation.Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

14 keywords...

hide…